World Vape Day 2025 Marks 20 Years of Tobacco Harm Reduction Progress
BRUSSELS, May 30, 2025 (GLOBE NEWSWIRE) -- Today, the global vaping community celebrates World Vape Day 2025, highlighting two decades of innovation and scientific advancement in tobacco harm reduction. This year's theme, '20 Years of Facts', underscores the growing body of evidence supporting vaping as a less harmful alternative to smoking and its role in helping millions of adults quit combustible tobacco.
World Vape Day is celebrated one day before World No Tobacco Day, emphasising the importance of evidence-based harm reduction tools in the fight against smoking-related disease. Since the introduction of modern vaping devices in 2003 and their subsequent arrival and uptake in Europe and the US, vaping has become a cornerstone of smoking cessation worldwide.
Countries such as Sweden, the UK, and New Zealand, which have embraced tobacco harm reduction policies and ensured access to regulated vaping products, now report record-low smoking rates. Sweden, for example, is poised to become the first smoke-free country in Europe, defined as having fewer than 5% daily smokers—an achievement attributed to widespread acceptance of safer nicotine alternatives. In contrast, nations with restrictive policies continue to lag behind in reducing smoking prevalence.
Despite robust scientific consensus, misinformation and regulatory barriers persist. Many health advocates warn that bans and flavour restrictions risk reversing progress by pushing former smokers back to cigarettes. 'Persistent misperceptions about the relative risks of vaping versus smoking remain a significant challenge, with studies showing that a majority of smokers in many countries still believe vaping is as harmful or more harmful than smoking,' commented Michael Landl, Director of the World Vapers' Alliance.
World Vape Day is a reminder for policymakers, public health officials, and the media to prioritise facts over fear and to recognise the real-world impact and potentials of harm reduction. Advocates stress that an inclusive, evidence-based approach is essential to accelerate progress towards global smoke-free goals and to ensure that adult smokers have access to effective alternatives.
For more information, campaign resources, and a full list of 20 facts about vaping and harm reduction, visit https://worldvapersalliance.com/world-vape-day/.
Media Contact: Michael Landl World Vapers' Alliance info@worldvapersalliance.comworldvapersalliance.com
A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/7c5dd147-1785-4bb0-8249-4ab534f51783Sign in to access your portfolio
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Upturn
19 hours ago
- Business Upturn
Cicero Statement on Trump's EO to Restore Order and Accountability in Homelessness Policy
By GlobeNewswire Published on July 25, 2025, 22:16 IST Austin, TX, July 25, 2025 (GLOBE NEWSWIRE) — Cicero Action proudly supports President Trump's Executive Order cracking down on encampments, defunding failed housing-first programs, promoting treatment for the homeless, and restoring authority to local leaders ready to act. For years, federal policy has enabled lawlessness—protecting unlawful encampments, subsidizing addiction, and ignoring serious mental illness. This executive order is a direct challenge to the activist-led industrial complex that profits from permanent homelessness and blocks reform. It backs law enforcement, prioritizes treatment over tents, and sends a clear message: cities don't have to tolerate chaos. 'Cities shouldn't have to choose between public safety and compassion,' said Devon Kurtz, Public Safety Policy Director at Cicero Institute. 'This order gives local leaders the legal tools and financial support they need to clear dangerous encampments and move people into real care.' The order directs federal agencies to withhold funding from jurisdictions that tolerate open drug use and squatting, encourages states to expand involuntary treatment laws, and allows cities to prioritize housing for women and children by separating them from known sex offenders. These are the very reforms Cicero Action has championed in states like Kentucky, Texas, and Florida—where voters demanded bold action and courageous lawmakers delivered. This order gives other bold states the green light to follow their lead. Cicero Action encourages governors, attorneys general, and state lawmakers across the country to use this moment. Build on this order. Strengthen civil commitment laws. Shut down illegal encampments. And stop sending taxpayer money to nonprofits that enable human suffering. The public is done waiting. It's time to act. Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. Business Upturn takes no editorial responsibility for the same. Ahmedabad Plane Crash GlobeNewswire provides press release distribution services globally, with substantial operations in North America and Europe.
Business Upturn
19 hours ago
- Business Upturn
Toll Brothers Announces New Lake Las Vegas Community Now Open in Henderson, Nevada
HENDERSON, Nev., July 25, 2025 (GLOBE NEWSWIRE) — Toll Brothers, Inc. (NYSE:TOL), the nation's leading builder of luxury homes, today announced the grand opening of Incanta Lago , a new gated community in Henderson, Nevada. Situated in the prestigious Lake Las Vegas master plan, Incanta Lago features luxurious single- and two-story homes offering refined lakeside living. The Toll Brothers Sales Center is now open at 427 Terra Alta in Henderson. Incanta Lago offers residents a private retreat featuring serene home sites, some with direct lake access, and exquisite home designs boasting modern open-concept floor plans and outdoor living space options perfect for entertaining. Home shoppers can personalize each home to suit their individual tastes, with options including flex spaces, rooftop terraces, multigenerational living suites, and storefront windows. 'Incanta Lago offers a unique blend of luxury and lifestyle with its stunning home designs and the vibrant amenities of Lake Las Vegas,' said Janet Love, Division President of Toll Brothers in Las Vegas. 'This community is perfect for those seeking a sophisticated and active lifestyle in a beautiful lakeside setting.' Incanta Lago residents will enjoy access to an abundance of upscale shopping, fine dining, and recreational opportunities within Lake Las Vegas and the surrounding area. Championship golf at The Reflection Bay Golf Club, picturesque trails, and exciting water sport activities are just steps away. Incanta Lago offers homes ranging from 2,488 to 3,293 square feet, with 3 to 4 bedrooms, up to 4.5 baths, and 2-car garages. Home prices start from the low $900,000s. Toll Brothers customers will experience one-stop shopping at the state-of-the-art Toll Brothers Design Studio, where customers can choose from a wide array of selections to personalize their dream home with the assistance of a Toll Brothers professional Design Consultant. For more information on Incanta Lago, prospective customers are invited to call (855) 700-8655 or visit About Toll Brothers Toll Brothers, Inc., a Fortune 500 Company, is the nation's leading builder of luxury homes. The Company was founded 58 years ago in 1967 and became a public company in 1986. Its common stock is listed on the New York Stock Exchange under the symbol 'TOL.' The Company serves first-time, move-up, empty-nester, active-adult, and second-home buyers, as well as urban and suburban renters. Toll Brothers builds in over 60 markets in 24 states: Arizona, California, Colorado, Connecticut, Delaware, Florida, Georgia, Idaho, Indiana, Maryland, Massachusetts, Michigan, Nevada, New Jersey, New York, North Carolina, Oregon, Pennsylvania, South Carolina, Tennessee, Texas, Utah, Virginia, and Washington, as well as in the District of Columbia. The Company operates its own architectural, engineering, mortgage, title, land development, smart home technology, and landscape subsidiaries. The Company also develops master-planned and golf course communities as well as operates its own lumber distribution, house component assembly, and manufacturing operations. Toll Brothers has been one of Fortune magazine's World's Most Admired Companies™ for 10+ years in a row, and in 2024 the Company's Chairman and CEO Douglas C. Yearley, Jr. was named one of 25 Top CEOs by Barron's magazine. Toll Brothers has also been named Builder of the Year by Builder magazine and is the first two-time recipient of Builder of the Year from Professional Builder magazine. For more information visit . From Fortune, ©2025 Fortune Media IP Limited. All rights reserved. Used under license. Contact: Andrea Meck | Toll Brothers, Senior Director, Public Relations & Social Media | 215-938-8169 | [email protected] A photo accompanying this announcement is available at Sent by Toll Brothers via Regional Globe Newswire (TOLL-REG) Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. Business Upturn takes no editorial responsibility for the same. Ahmedabad Plane Crash
Business Upturn
a day ago
- Business Upturn
Sobi Announces U.S. Food and Drug Administration Approves Doptelet® (avatrombopag) for the Treatment of Thrombocytopenia in Pediatric Patients One Year and Older with Persistent or Chronic Immune Thrombocytopenia (ITP)
Doptelet Sprinkle (avatrombopag) was approved as an effective formulation for children one year to less than six years. The primary endpoint was met in 27.8% of patients, confirming the efficacy in children and adolescents with persistent or chronic ITP WALTHAM, Mass., July 25, 2025 (GLOBE NEWSWIRE) — Sobi North America, the North American affiliate of Swedish Orphan Biovitrum AB (Sobi®), today announced that the U.S. Food and Drug Administration (FDA) approved Doptelet® (avatrombopag) for the treatment of thrombocytopenia in pediatric patients one year and older with persistent or chronic immune thrombocytopenia (ITP) who have had an insufficient response to a prior therapy. 1 The approval also includes a new formulation, Doptelet Sprinkle (avatrombopag) oral granules, for use in children ages one to less than six years. 1 'Doptelet represents a significant advancement in the treatment of children and adolescents with persistent or chronic ITP,' said Rachael Grace, MD, MMSc, Pediatric Hematologist and Director, Hematology Clinical Research at Dana-Farber/Boston Children's Cancer and Blood Disorders Center, and lead investigator of the AVA-PED-301 study. 'This therapy offers simple, flexible administration because it is oral, available as a tablet and now as a new pediatric sprinkle formulation and has no food restrictions. The approval of Doptelet for pediatric ITP offers families a new treatment option that can help address challenges in managing ITP in pediatric patients.' Doptelet Sprinkle is the approved dosage form for patients aged one to less than six years, while Doptelet tablet is the approved dosage form for patients aged six and up. 1 The pediatric approval is based on results from AVA-PED-301, a global, randomized, phase 3 study evaluating the efficacy, safety, and pharmacokinetics of Doptelet in the treatment of pediatric subjects with ITP. The study showed that 27.8% of Doptelet patients achieved the primary endpoint of durable platelet response* versus 0% of placebo patients in the absence of rescue medication (p=0.0077, 95% CI 15.8-39.7). Also, 81.5% of Doptelet patients achieved the alternative primary endpoint of platelet response** versus no patients in the placebo group (p=<0.0001, 95% CI 71.1-91.8). At Day 8, 55.6% of Doptelet patients (95% CI: 41.4%, 69.1%) had a platelet count ≥50×10^9/L in the absence of rescue therapy (p<0.0001) versus no placebo patients (95% CI: 0.0%, 16.1%). Doptelet was generally well-tolerated. In pediatric patients with persistent or chronic immune thrombocytopenia, the most common adverse reactions (≥ 10%) were viral infection, nasopharyngitis, cough, pyrexia, and oropharyngeal pain.1 'Since its introduction in 2019, Doptelet has been a cornerstone therapy for chronic ITP in adults,' said Duane Barnes, President of Sobi North America. 'This approval not only reinforces our commitment to innovation but also allows us to expand the treatment experience for patients and their families by offering Doptelet in two formulations.' Immune thrombocytopenia (ITP) is an autoimmune disorder characterized by low numbers of platelets, leading to bruising and an increased risk of bleeding. It is estimated up to 100 people per million live with ITP. In children, ITP occurs in five out of 100,000 children per year and up to 25% of newly diagnosed pediatric ITP patients develop chronic ITP. Currently, no cure is available, and patients usually relapse after various treatments. Indications Doptelet is a thrombopoietin receptor agonist indicated for the treatment of: Thrombocytopenia in adult patients with chronic liver disease who are scheduled to undergo a procedure. Thrombocytopenia in adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment Thrombocytopenia in pediatric patients 1 year and older with persistent or chronic immune thrombocytopenia who have had an insufficient response to a previous treatment Important Safety Information Doptelet is a thrombopoietin (TPO) receptor agonist and TPO receptor agonists have been associated with thrombotic and thromboembolic complications in patients with chronic liver disease or immune thrombocytopenia. In patients with chronic liver disease, thromboembolic events (portal vein thrombosis) occurred in 0.4% (1/274) of patients receiving Doptelet. In adult patients with chronic immune thrombocytopenia, thromboembolic events (arterial or venous) occurred in 7% (9/128) of patients receiving Doptelet. Doptelet should not be administered to patients with chronic liver disease or immune thrombocytopenia in an attempt to normalize platelet counts. The most common adverse reactions in clinical trials were viral infection, nasopharyngitis, cough, pyrexia, and oropharyngeal pain. To report SUSPECTED ADVERSE REACTIONS, contact Sobi, Inc. at 1-866-773-5274 or FDA at 1-800-FDA-1088 or Please see the full Prescribing Information for Doptelet. * A durable response consisted of patients achieving a platelet count >=50,000/uL for six of the last eight weeks in the 12-week core phase of the AVA-PED-301 study. ** Efficacy was also evaluated by platelet response, defined as the proportion of subjects achieving at least two consecutive platelet assessments ≥50×10^9/L in the core phase in the absence of rescue medication. About Immune thrombocytopenia (ITP) Immune thrombocytopenia (ITP) is a rare, acquired autoimmune condition characterized by a low platelet count and an increased risk of bleeding, and represents a multi-faceted disease burden for children and adolescents. Bleeding can range from minor symptoms, such as bruising, to more severe findings such as intracranial hemorrhage. ITP can also have a significant impact on quality of life including severe fatigue and restrictions on physical activity due to risk of bleeding. About Doptelet® (avatrombopag) Doptelet is an orally administered thrombopoietin receptor agonist (TPO-RA) that mimics the biologic effects of TPO in stimulating the development and maturation of megakaryocytes, resulting in increased platelet count. It is approved by the US Food & Drug Administration (FDA) for the treatment of thrombocytopenia in adult patients with chronic liver disease who are scheduled to undergo a procedure and by the European Medicines Agency (EMA) for the treatment of severe thrombocytopenia in adult patients with chronic liver disease (CLD) who are scheduled to undergo an invasive procedure. In June 2019, Doptelet was approved by the FDA for the treatment of thrombocytopenia in adult patients with chronic immune thrombocytopenia (ITP) who have had an insufficient response to a previous treatment and in 2021, Doptelet was approved by EMA for the treatment of primary chronic ITP in adult patients who are refractory to other treatments (e.g. corticosteroids, immunoglobulins). About Sobi North America As the North American affiliate of international biopharmaceutical company Sobi, the Sobi North America team is committed to Sobi's vision of being a leader in providing innovative treatments that transform lives for individuals with rare diseases. Our product portfolio includes multiple approved treatments focused on immunology, hematology and specialty care. With U.S. headquarters in the Boston area, Canadian headquarters in the Toronto area, and field sales, medical and market access representatives spanning North America, our growing team has a proven track record of commercial excellence. More information is available at or at About Sobi® Sobi is a global biopharma company unlocking the potential of breakthrough innovations, transforming everyday life for people living with rare diseases. Sobi has approximately 1,900 employees across Europe, North America, the Middle East, Asia and Australia. In 2024, revenue amounted to SEK 26 billion. Sobi's share (STO:SOBI) is listed on Nasdaq Stockholm. More about Sobi at and LinkedIn. Contacts For details on how to contact the Sobi Investor Relations Team, please click here. For Sobi Media, click here. References 1. Doptelet Prescribing Information. Doptelet U.S. Product Information. Last updated: July 2025. Morrisville, NC: AkaRx, Inc. Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. Business Upturn takes no editorial responsibility for the same. Ahmedabad Plane Crash
